The result of the project will be the development of an innovative ophthalmic drug dispensing system. During the project implementation, it is planned to design and develop an innovative medical device that will significantly improve the effectiveness and safety process as well as the effectiveness of ophthalmic therapy, including patient’s compliance issue.

Passio worked out the concept of the device, which in its assumption will be distinguished by a special handy construction, which will be significant facilitation for people with disabilities within the musculoskeletal system, visually impaired patients, as well as elderly patients and children. The main assumption of the designed product is to equip it with the characteristics of a device, to provide the patient with the ability to correctly and precisely apply the ophthalmic drug. The applicator developed within the framework of the project will be characterized by an ergonomic shape and low weight, which will allow comfortable one – hand operation.

In addition, the implemented technological and constructional solutions will allow applying the appropriate dose (volume) of the drug in the form of eye drops directly on the surface of the eye and/or into the conjunctival sac, without the need of using preservatives in the therapeutic solution.

Undoubtedly, the ability to communicate is the basis for proper functioning within the contemporary information society we live in. Diseases of the sense organs – including the eyes, are therefore a challenge not only from the point of view of individual and public health but also because of social and civilizational dependencies. The loss of sight, the basic organ of the human sense of mind, is one of the most traumatic experiences that can happen, often resulting in exclusion from social life. Hence, the need for special consideration of ophthalmologic problems in on the top of the list of health priorities.

According to the World Health Organization (WHO), vision diseases affect 285 million people around the world, of which 39 million are classified as blind, and the remaining 246 million are characterized by a lower or higher visual impairment.